Cargando…

Exceptional responses to PARP inhibitors in patients with metastatic breast cancer in oncologic crisis

PURPOSE: Cancers deficient in homologous recombination DNA repair, such as those with BRCA1 or BRCA2 (BRCA1/2) mutations rely on a pathway mediated by the enzyme poly(adenosine diphosphate-ribose) polymerase (PARP). PARP inhibitors (PARPi’s) have demonstrated efficacy in treating patients with germl...

Descripción completa

Detalles Bibliográficos
Autores principales:	Cheng, Joyce M., Canzoniero, Jenna, Lee, Seoho, Soni, Sudeep, Mangini, Neha, Santa-Maria, Cesar A.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Springer US 2023
Materias:	Brief Communication
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10065997/ https://www.ncbi.nlm.nih.gov/pubmed/37002487 http://dx.doi.org/10.1007/s10549-023-06910-6

Ejemplares similares

Pharmacokinetics and Pharmacodynamics of PARP Inhibitors in Oncology
por: Bruin, Maaike A. C., et al.
Publicado: (2022)

PARP inhibitors in metastatic prostate cancer
por: Taylor, Amy K., et al.
Publicado: (2023)

Mechanisms of resistance to PARP inhibitors - an evolving challenge in oncology
por: Mweempwa, Angela, et al.
Publicado: (2019)

Whole-exome sequencing of long-term, never relapse exceptional responders of trastuzumab-treated HER2+ metastatic breast cancer
por: Walsh, Naomi, et al.
Publicado: (2020)

PARP Inhibitors in Metastatic Prostate Cancer: Evidence to Date
por: Nizialek, Emily, et al.
Publicado: (2020)

PARP Inhibitors in Breast and Ovarian Cancer
por: Wang, Samuel S. Y., et al.
Publicado: (2023)

Associations with response to Poly(ADP-ribose) Polymerase (PARP) inhibitors in patients with metastatic breast cancer
por: Desnoyers, A., et al.
Publicado: (2022)

An Overview of PARP Inhibitors for the Treatment of Breast Cancer
por: Cortesi, Laura, et al.
Publicado: (2021)

Emerging Role of PARP Inhibitors in Metastatic Triple Negative Breast Cancer. Current Scenario and Future Perspectives
por: Barchiesi, Giacomo, et al.
Publicado: (2021)

Combining PARP inhibitors and platinum-based chemotherapy in metastatic triple negative and/or BRCA-associated breast cancer
por: Molto Valiente, Consolacion, et al.
Publicado: (2023)

PARP inhibitors
por: Anwar, Maheen, et al.
Publicado: (2015)

Increasing Medical Student Engagement Through Virtual Rotations in Radiation Oncology
por: Kahn, Jenna M., et al.
Publicado: (2020)

Biogenesis of reproductive PhasiRNAs: exceptions to the rules
por: Zheng, Jiakun, et al.
Publicado: (2022)

Adverse kidney outcomes of CDK 4/6 inhibitors for metastatic breast cancer
por: Hanna, Paul E., et al.
Publicado: (2023)

Stabilization of bone marrow infiltration by metastatic breast cancer with continuous doxorubicin
por: Pahouja, Gaurav, et al.
Publicado: (2014)

Advances in the use of PARP inhibitor therapy for breast cancer
por: McCann, Kelly E, et al.
Publicado: (2018)

PARP-1 protein expression in glioblastoma multiforme
por: Galia, A., et al.
Publicado: (2012)

Clinical Development of PARP Inhibitors in Treating Metastatic Castration-Resistant Prostate Cancer
por: Adashek, Jacob J., et al.
Publicado: (2019)

Therapeutic Potential of PARP Inhibitors in the Treatment of Metastatic Castration-Resistant Prostate Cancer
por: Jang, Albert, et al.
Publicado: (2020)

PARP inhibitors and metastatic castration-resistant prostate cancer: uture directions and pitfalls
por: Franza, A., et al.
Publicado: (2021)

BRCA1/2 Reversion Mutations in Patients Treated with Poly ADP-Ribose Polymerase (PARP) Inhibitors or Platinum Agents
por: Darabi, Sourat, et al.
Publicado: (2022)

A HUWE1 defect causes PARP inhibitor resistance by modulating the BRCA1-∆11q splice variant
por: Pettitt, Stephen J., et al.
Publicado: (2023)

PARP inhibitors: the race is on
por: Brown, Jessica S, et al.
Publicado: (2016)

PET/CT Imaging in Oncology: Exceptions That Prove the Rule
por: Casali, M., et al.
Publicado: (2013)

Efficacy and Safety of PARP Inhibitors in Advanced or Metastatic Triple-Negative Breast Cancer: A Systematic Review and Meta-Analysis
por: Liu, Xu, et al.
Publicado: (2021)

The ‘French exception’: the right to continuous deep sedation at the end of life
por: Horn, Ruth
Publicado: (2018)

Correlation Between PARP-1 Immunoreactivity and Cytomorphological Features of Parthanatos, a Specific Cellular Death in Breast Cancer Cells
por: Donizy, P., et al.
Publicado: (2013)

STING agonism enhances anti-tumor immune responses and therapeutic efficacy of PARP inhibition in BRCA-associated breast cancer
por: Pantelidou, Constantia, et al.
Publicado: (2022)

Translating the role of PARP inhibitors in triple-negative breast cancer
por: Beniey, Michèle, et al.
Publicado: (2019)

PARP Inhibitors in the Treatment of Early Breast Cancer: The Step Beyond?
por: Gonçalves, Anthony, et al.
Publicado: (2020)

PARP1 in Carcinomas and PARP1 Inhibitors as Antineoplastic Drugs
por: Wang, Luyao, et al.
Publicado: (2017)

Interactions of PARP1 Inhibitors with PARP1-Nucleosome Complexes
por: Maluchenko, Natalya, et al.
Publicado: (2022)

Maintenance therapies in metastatic pancreatic cancer: present and future with a focus on PARP inhibitors
por: Hammel, Pascal, et al.
Publicado: (2020)

Exceptional Response to A Single Cycle of Immunotherapy in a Lynch Syndrome Patient with Metastatic Pancreatic Adenocarcinoma
por: Patil, Neha R., et al.
Publicado: (2020)

Pilot Study: PARP1 Imaging in Advanced Prostate Cancer
por: Dehdashti, Farrokh, et al.
Publicado: (2022)

1-Oxo-3,4-dihydroisoquinoline-4-carboxamides as novel druglike inhibitors of poly(ADP-ribose) polymerase (PARP) with favourable ADME characteristics
por: Safrygin, Alexander, et al.
Publicado: (2021)

PARP inhibitors trap PARP2 and alter the mode of recruitment of PARP2 at DNA damage sites
por: Lin, Xiaohui, et al.
Publicado: (2022)

PARP inhibitors are not all equal
por: Dent, Paul
Publicado: (2013)

PARP inhibitors in ovarian cancer
por: Cibula, David, et al.
Publicado: (2015)

Dual Inhibitors of PARPs and ROCKs
por: Antolín, Albert A., et al.
Publicado: (2018)

Cannot write session to /tmp/vufind_sessions/sess_jjg2j1jmbcbajtperf71amuv02